Acadian Asset Management LLC reduced its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 7.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,781,746 shares of the biopharmaceutical company’s stock after selling 234,493 shares during the period. Acadian Asset Management LLC owned about 1.24% of Incyte worth $158,443,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Incyte by 48.8% during the fourth quarter. Wellington Management Group LLP now owns 131,649 shares of the biopharmaceutical company’s stock worth $8,266,000 after buying an additional 43,160 shares in the last quarter. Fulton Bank N.A. bought a new stake in shares of Incyte in the 1st quarter worth $1,425,000. ARK Investment Management LLC raised its holdings in shares of Incyte by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 531,625 shares of the biopharmaceutical company’s stock valued at $33,381,000 after purchasing an additional 37,932 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Incyte by 29.3% in the fourth quarter. Russell Investments Group Ltd. now owns 963,090 shares of the biopharmaceutical company’s stock valued at $60,465,000 after purchasing an additional 217,979 shares during the last quarter. Finally, Great Lakes Advisors LLC bought a new position in shares of Incyte during the fourth quarter valued at about $2,033,000. 96.97% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, insider Thomas Tray sold 1,093 shares of the company’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $58.91, for a total transaction of $64,388.63. Following the sale, the insider now directly owns 21,634 shares in the company, valued at $1,274,458.94. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Barry P. Flannelly sold 8,148 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $60.00, for a total value of $488,880.00. Following the sale, the executive vice president now owns 50,534 shares in the company, valued at $3,032,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas Tray sold 1,093 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $58.91, for a total value of $64,388.63. Following the transaction, the insider now owns 21,634 shares of the company’s stock, valued at $1,274,458.94. The disclosure for this sale can be found here. Insiders sold a total of 29,711 shares of company stock worth $1,786,941 in the last quarter. 17.50% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Report on Incyte
Incyte Stock Performance
INCY traded up $0.50 on Friday, hitting $65.87. The company’s stock had a trading volume of 1,559,059 shares, compared to its average volume of 2,837,766. Incyte Co. has a 12 month low of $50.27 and a 12 month high of $67.36. The firm has a market cap of $14.79 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 1.38 and a beta of 0.73. The company has a quick ratio of 3.43, a current ratio of 3.47 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $60.04 and its 200-day simple moving average is $58.63.
Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.31). The company had revenue of $880.89 million during the quarter, compared to the consensus estimate of $935.85 million. Incyte had a return on equity of 12.83% and a net margin of 19.78%. Analysts forecast that Incyte Co. will post 3.66 EPS for the current year.
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Articles
- Five stocks we like better than Incyte
- Insider Trades May Not Tell You What You Think
- Why This AI Stock is Rising Despite Tech Sell-Off
- About the Markup Calculator
- MarketBeat Week in Review – 7/15 – 7/19
- Health Care Stocks Explained: Why You Might Want to Invest
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.